Market Overview

Valeant Pharmaceuticals Acquires Visudyne From QLT for $62.5M

Share:
Related VRX
Rodman & Renshaw Reiterates Valeant Buy Rating On Back Of 2 Straight FDA Wins
The FDA Showing Valeant Some Love With Recent Drug Approvals
Biotech Forum Daily Digest: Will Biotech Finally Break Out? All Eyes On Gilead, Spotlight On Seres Therapeutics (Seeking Alpha)

Valeant Pharmaceuticals International (NYSE: VRX) announced today that it has acquired Visudyne, used to treat abnormal growth of leaky blood vessels in the eye caused by wet age-related macular degeneration, from QLT Inc. (NASDAQ: QLTI). Valeant paid $62.5 million upfront for all U.S. rights and available inventories for Visudyne, which had U.S. revenue of approximately $21 million in 2011, and another $50 million upfront for rights to non-US royalties on Visudyne sales, which were approximately $14 million in 2011. Valeant has also agreed to pay an additional $5 million in contingent payments relating to the development of QLT's laser program in the United States and up to $15 million in contingent payments relating to the non-U.S. royalties. Additionally, Valeant has manufacturing rights and assumed a supply agreement for outside of United States. The transaction is expected to be immediately accretive.

"We are excited about the opportunity to add a complementary product to our growing ophthalmology business," stated J. Michael Pearson, chairman and chief executive officer.  "Not only will we be able to use Visudyne to better leverage our current ophthalmology sales force with a complementary product to Macugen, we are

See full press release

Posted-In: News Guidance Management M&A Global

 

Related Articles (QLTI + VRX)

View Comments and Join the Discussion!